• Guard Therapeutics completed its reverse takeover of Disruptive Pharma, meeting all transaction conditions.
• The listed company will be renamed Disruptive Pharma, shifting focus to development and commercialization of Formulite drug-delivery technology.
• Industrifonden, an investor in Guard Therapeutics, welcomed completion of the transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Industrifonden published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein.